Cantor Fitzgerald Keeps a Hold Rating on Arrowhead Research (ARWR)

By Austin Angelo

Cantor Fitzgerald analyst Elemer Piros maintained a Hold rating on Arrowhead Research (ARWRResearch Report) today and set a price target of $50.00. The company’s shares closed last Monday at $48.17, close to its 52-week high of $49.78.

According to, Piros is ranked 0 out of 5 stars with an average return of -7.4% and a 37.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as PolarityTE, Mesoblast, and GW Pharma.

Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $54.25.

See today’s analyst top recommended stocks >>

Based on Arrowhead Research’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $20.34 million. In comparison, last year the company had a GAAP net loss of $10.76 million.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year. Earlier this month, Kenneth Allen Myszkowski, the CFO of ARWR bought 12,649 shares for a total of $65,648.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.